

New Government restrictions on use of Puberty Suppressing Hormones (Puberty Blockers); Information for prescribers and pharmacists/dispensing doctors

The Government has introduced emergency restrictions on the use of **gonadotrophin releasing hormone (GnRH) analogues** used to suppress puberty as part of treating gender incongruence or gender dysphoria in children and young people who are under 18 years of age. Some of these restrictions, the ones for private prescriptions, will take effect from 3 June 2024.

<https://www.gov.uk/government/news/new-restrictions-on-puberty-blockers>

Who will the change affect most?

As a result of this new Government policy, people who are currently receiving a private prescription for GnRH analogues for any reason from a professional who is in the European Economic Area (EEA) or Switzerland, but not UK registered, will be impacted from 3 June 2024. **Pharmacies in Great Britain will no longer be able to dispense new private prescriptions, dated on or after 3 June 2024 for GnRH analogues from the EEA or Switzerland for anyone under 18 years old.**

Who will be less affected but may need advice and reassurance?

Individuals who are already receiving NHS or private prescriptions can continue to receive their prescriptions. However, they and / or their families are strongly advised to meet with their prescribing clinician to fully understand the safety risks associated with GnRH analogues when prescribed for gender incongruence or gender dysphoria. Information for patients can be found on the website for the [NHS National Referral Support Service for the Children and Young People's Gender Service](#).

What are the specifics of the new Government Policy?

As a result of the new Government policy, it will become a **criminal offence** for a doctor, pharmacist, or any other individual in Great Britain to sell or supply these drugs to patients under the age of 18 **except in the following circumstances:**



- The child or young person is prescribed these medicines on an NHS prescription (for example, from the NHS Children and Young People’s Gender Service). All NHS prescriptions and directions are outside of this ban.
- The child or young person is prescribed these medicines on a private prescription from a UK prescriber that fulfils the following criteria:
 - The prescription was dated prior to 3 June 2024; or
 - It is a repeat prescription but only when the initial prescription was written in the six months prior to 3 June 2024;
 - There are also requirements for prescriptions issued from 3 June 2024 to be marked with the person’s age, annotated by the prescriber with “SLS”, and in the case of prescriptions issued before that date, for the person to provide proof of identity and age.
 - The prescription is for a purpose other than the treatment of gender incongruence or gender dysphoria, or for gender incongruence/dysphoria if the patient started treatment for gender incongruence/dysphoria before 3 June 2024.

Additionally, from 26 June 2024 General Practitioners (GPs) in England will only be able to supply prescriptions for GnRH analogues in the following circumstances:

- The patient is aged 18 years or over; or
- The patient is under 18 years old, and the purpose of the prescription is for a medical condition other than gender incongruence or gender dysphoria; or
- The patient is under 18 years old and has started treatment with these medicines, and for these purposes they will be treated as having started treatment if they have been issued with a prescription for these medicines since 3 December 2023, even if they have not yet started taking the medicines.

As indicated above, new private prescriptions for GnRH analogues from a prescriber in the European Economic Area (EEA) or Switzerland who is not UK registered are banned from being supplied in Great Britain in all circumstances for patients aged under 18. For patients aged 18 or over with a prescription from an EEA or Switzerland registered prescriber, their prescription can be dispensed in Great Britain providing verification of age and identity can be shown to the dispensing pharmacist.

The effect of the order is that emergency supply under the Human Medicines Regulations 2012 is prohibited.



Further information about specific cases can be found in Appendix 1.

These changes will be reflected in the Drug Tariff from July 2024, and in dm+d this week. It will take time for these changes to be added to GP prescribing and pharmacy dispensing IT systems. Further advice will be provided on IT system changes ahead of 26 June 2024.

Support for children and young people affected by this change

Some children and young people may be concerned or distressed by changes. If they are already under the care of Childrens and Young People's (CYP) mental health provider/Child and Adolescent Mental Health Services (CAMHS) they can contact their team for advice. If they are not, their GP team will be able to assess whether further referrals for mental health support are required. Patients can also be signposted to advice on getting mental health support available at [nhs.uk](https://www.nhs.uk). Anyone in need of urgent support can contact NHS 111 and choose the mental health option (option 2) <https://www.nhs.uk/nhs-services/mental-health-services/where-to-get-urgent-help-for-mental-health/>

NHS England published national clinical policy on puberty suppressing hormones on 12 March 2024 alongside an evidence review which can be found [here](#).

The General Pharmaceutical Council has published a resource for pharmacy professionals to support them in providing information, support and services to children and young people with gender incongruence or dysphoria; 'Gender identity services for children and young people: making compassionate, professional and ethical decisions' is available at: [Gender identity services for children and young people: making compassionate, professional and ethical decisions \(pharmacyregulation.org\)](https://www.pharmacyregulation.org)



Appendix 1

ADVICE FOR PRESCRIBERS AND DISPENSERS

Puberty Suppressing Hormones			
Patient group	Advice	Prescriber	Dispenser
Under 18 years old and not prescribed GnRH analogues.	No under 18-year-old should be started on GnRH analogues to suppress puberty for gender incongruence or gender dysphoria.	<p>The initiation of GnRH analogues is not possible in the NHS specialist Children and Young People's Gender Service unless this is part of a future NIHR research study or the patient was referred to an NHS paediatric endocrinology team for assessment of suitability of GnRH analogues for gender incongruence or gender dysphoria on or before 31 March 2024.</p> <p>Other NHS clinicians cannot initiate a new NHS prescription from 26 June 2024.</p> <p>Private practitioners cannot initiate a new prescription from 3 June 2024 to patients who have not yet started treatment.</p>	<p>Pharmacies in Great Britain cannot dispense a new (initiation) prescription issued by a prescriber, unless the patient started treatment before the restrictions came into effect.</p> <p>This includes prescriptions issued in the UK, European Economic Area (EEA) or Switzerland.</p>
Patient is under 18	Patients under 18 are strongly	If during a shared decision-making	NHS primary care prescriptions for continuation



<p>years old and already being prescribed GnRH analogues through the NHS for gender incongruence or gender dysphoria.</p>	<p>advised to meet with their clinician to fully understand the risks of continuing taking GnRH analogues for puberty suppression.</p> <p>These medications can be stopped and do not need to be weaned off.</p>	<p>conversation considering the risks a decision is made to continue the Children and Young People Gender Service or another NHS clinician can continue to prescribe. NHS prescriptions in primary care must be marked SLS if they are issued on or after 26 June 2024.</p>	<p>of existing treatment marked SLS may be dispensed when the new restrictions come into force on 26 June. NHS prescriptions are not covered by the Prohibition Order.</p>
<p>Patient is under 18 years old and is already being prescribed GnRH analogues by a UK-registered private practitioner in Great Britain for gender incongruence or gender dysphoria.</p>	<p>Patients under 18 are strongly advised to meet with their clinician to fully understand the risks of continuing taking GnRH analogues for puberty suppression.</p> <p>These medications can be stopped and do not need to be weaned off.</p>	<p>If during a shared decision-making conversation considering the risks a decision is made to continue the private practitioner can continue to prescribe. New prescriptions must be marked SLS and include the patient's age.</p>	<p>Private prescriptions for continuation of existing treatment marked SLS and including the patient's age may be dispensed . Existing prescriptions, issued before 3 June 2024, can only be supplied if proof of age and identity is produced.</p>
<p>Patient under 18 years old and is already being prescribed GnRH analogues through a prescription from the EEA or Switzerland for gender incongruence</p>	<p>Patients under 18 are strongly advised to meet with their clinician to fully understand the risks of continuing taking GnRH analogues for puberty suppression.</p>	<p>If the patient wants to continue an NHS or private prescriber can continue to prescribe following a shared decision-making conversation about the risks with the patient. Prescription must be marked SLS</p>	<p>Prescriptions from EEA or Switzerland for GnRH analogues for puberty suppression can no longer be dispensed unless they were issued before 3 June 2024 and are still valid, and the dispenser has proof of age and identity.</p>



or gender dysphoria.	These medications can be stopped and do not need to be weaned off.	and patient's age, if issued after 3 June 2024.	
Patient is under 18 years old and is an overseas visitor who has run out of their GnRH analogues for gender incongruence or gender dysphoria.	The patient may see a private practitioner, or temporarily register with a GP for advice and support.	If the patient started treatment before 3 June 2024, the private practitioner or the GP can prescribe a repeat prescription if this is within their clinical scope of practice, and they are satisfied this is urgently needed continuation therapy. Prescription must be marked SLS and have proof of age.	The patient should secure further medications from their home nation specialist if possible. However, a private prescription marked SLS from 3 June 2024, or an NHS prescription marked SLS from 26 June 2024, for continuation of treatment may be dispensed.
Patient is 18 years or older and remains on GnRH analogues and have not started on gender affirming hormones.	Patients under 18 are strongly advised to meet with their clinician to fully understand the risks of continuing taking GnRH analogues for puberty suppression. These medications can be stopped and do not need to be weaned off.	Patients are advised to meet with their clinician so that the risks of continuation are fully understood. If after a shared decision-making conversation, the patient wishes to continue treatment the practitioner can continue NHS or private prescribing. Prescription must be marked SLS.	Prescriptions from NHS from 26 June 2024, or private prescribers from 3 June 2024, marked SLS may be dispensed. In the latter case, if it is not marked SLS, the patient may instead provide proof of age and identity. Prescriptions from the EEA or Switzerland can be dispensed if the patient is able to provide proof of age and identity. SLS cannot be used by such prescribers.
Gender Affirming Hormones (GnRH analogue prescriptions)			
Patient is under 18 years old and not yet taking	No under 18-year-old should be initiated on gender affirming	NHS prescribers are advised not to initiate gender affirming	NHS GnRH analogue prescriptions may not be dispensed unless marked SLS.



gender affirming hormones.	hormones by the NHS (except by Children and Young People's Gender Service in extreme circumstances).	hormones under the age of 18. Children and Young People's Gender Service will consider initiating this treatment in extreme circumstances. A private practitioner may after a shared decision-making conversation about the risks initiate prescriptions for GnRH analogues as part of gender affirmation. Prescription must be marked SLS.	Private prescriptions marked SLS may be dispensed. Prescriptions from the EEA or Switzerland for GnRH analogues cannot be dispensed.
Patient is under 18 years old and is already being prescribed GnRH analogues by the NHS as part of gender affirmation.	Patients are advised to continue taking GnRH analogues as part of gender affirmation. They should consult their prescriber if they wish to consider withdrawing.	Patients should have a shared decision-making conversation about risks of treatment with the CYP Gender Service or other NHS prescriber. If the patient decides to continue treatment this can be prescribed. Prescription must be marked SLS.	NHS prescriptions continuing treatment marked SLS may be dispensed.
Patient is under 18 years old and is already being prescribed GnRH analogues by a private practitioner in	Patients are advised to continue taking GnRH analogues as part of gender affirmation. They should consult their prescriber if	Patients should have a shared decision-making conversation about risks of treatment with their private prescriber. If the patient wishes to	Private and NHS prescriptions for continuation of treatment marked SLS may be dispensed. Prescriptions from the EEA or Switzerland for GnRH analogues cannot be dispensed.



England as part of gender affirmation.	they wish to consider withdrawing.	continue treatment the private practitioner (or an NHS prescriber, where appropriate) can continue to prescribe. Prescription must be marked SLS.	
Patient is under 18 years old and is already being prescribed GnRH analogues through a prescription from the EEA or Switzerland as part of gender affirmation.	This treatment should <u>not</u> be withdrawn abruptly. Patients are advised to meet with the clinician who initiated treatment for further advice and support. If that is not possible, they should meet with their GP or specialist to consider options.	Private or NHS prescribers may prescribe treatment for these patients following a shared decision-making conversation about the risks of treatment. Prescription must be marked SLS.	Prescriptions from EEA or Switzerland for GnRH analogues cannot be dispensed. NHS or private prescriptions marked SLS may be dispensed.
Patient is under 18 years old visiting the UK and has run out of their GnRH analogues as part of gender affirmation.	The patient may see a private practitioner, or temporarily register with a GP for advice and support.	The private or NHS prescriber can prescribe a repeat prescription if this is within their clinical scope of practice, and they are satisfied this is urgently needed continuation therapy. Prescription must be marked SLS.	The patient should secure further medications from their home nation specialist if possible. However, a private or NHS prescription for continuation of treatment may be dispensed. Prescriptions from the EEA or Switzerland for GnRH analogues cannot be dispensed.
Patient is over 18 years old	The patient may see a private practitioner, or	The private or NHS prescriber can prescribe a	Prescriptions from NHS prescribers marked SLS may be dispensed if the patient is



<p>visiting the UK and has run out of their GnRH analogues as part of gender affirmation.</p>	<p>temporarily register with a GP for advice and support.</p>	<p>repeat prescription if this is within their clinical scope of practice, and they are satisfied this is urgently needed continuation therapy. Prescription must be marked SLS.</p>	<p>able to provide proof of age and identity. Prescriptions from private prescribers, if not marked SLS, the patient may instead provide proof of age and identity.</p> <p>Prescriptions from the EEA or Switzerland can be dispensed if the patient is able to provide proof of age and identity.</p>
<p>Prescriptions for GnRH analogues for conditions not including gender dysphoria or gender incongruence</p>			
<p>Patient is under 18 years old and is already being prescribed GnRH analogues for other reasons.</p>	<p>NHS and private patients can continue to receive prescriptions.</p> <p>Patients receiving a prescription from an EEA or Swiss registered prescriber are advised to seek advice from their GP or private practitioner.</p>	<p>NHS and private prescriptions can be issued.</p> <p>Both NHS and private prescriptions for GnRH analogues need to be endorsed SLS by the prescriber to demonstrate that the prescription is in accordance with the new arrangements.</p>	<p>Both NHS and private prescriptions endorsed SLS can be dispensed.</p> <p>Prescriptions from the EEA or Switzerland registered for GnRH analogues cannot be dispensed.</p>
<p>Patient 18 years old and over who are already being prescribed GnRH analogues for other reasons.</p>	<p>Patients will be able to continue to receive their prescriptions.</p>	<p>Both NHS and private prescriptions for GnRH analogues need to be endorsed SLS by the prescriber to demonstrate that the prescription is in accordance with the new arrangements.</p>	<p>Prescriptions from NHS prescribers marked SLS may be dispensed if the patient is able to provide proof of age and identity. Prescriptions from private prescribers, if not marked SLS, the patient may instead provide proof of age and identity.</p> <p>Prescriptions from the EEA or Switzerland can be dispensed if the patient is able to provide proof of age and identity.</p>

